Literature DB >> 10617302

Anti-human procathepsin D activation peptide antibodies inhibit breast cancer development.

V Vetvicka1, J Vetvickova, M Fusek.   

Abstract

Enzymatically inactive procathepsin D secreted from cancer cells has been confirmed to play a role in development of human breast cancer. In the present study, we focused on the role of activation peptide which was in our preliminary studies suggested to be most probably responsible for mitogenic activity of procathepsin D. Using synthetic fragments and antibodies raised against individual fragments, we demonstrated that the growth factor activity of activation peptide is localized in a nine amino acid stretch (AA 36-44) of activation peptide and moreover both anti-activation peptide and anti-27-44 peptide antibodies administered in vivo inhibited the growth of human breast tumors in athymic nude mice. Taking into account our previous results and presented data, we hypothesize that the interaction of procathepsin D activation peptide with an unknown surface receptor is mediated by a sequence 36-44 plus close vicinity. We also propose that this interaction leads in certain types of tumor derived cell lines to proliferation and higher motility. Blocking of the interaction of activation peptide by specific antibodies or antagonists might be a valuable tool in breast cancer inhibition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10617302     DOI: 10.1023/a:1006238003772

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  12 in total

1.  Procathepsin D secreted by HaCaT keratinocyte cells - A novel regulator of keratinocyte growth.

Authors:  Aruna Vashishta; Sujata Saraswat Ohri; Jana Vetvickova; Martin Fusek; Jitka Ulrichova; Vaclav Vetvicka
Journal:  Eur J Cell Biol       Date:  2007-06       Impact factor: 4.492

2.  Procathepsin D and cancer: From molecular biology to clinical applications.

Authors:  Vaclav Vetvicka; Aruna Vashishta; Sujata Saraswat-Ohri; Jana Vetvickova
Journal:  World J Clin Oncol       Date:  2010-11-10

3.  A replacement of the active-site aspartic acid residue 293 in mouse cathepsin D affects its intracellular stability, processing and transport in HEK-293 cells.

Authors:  Sanna Partanen; Stephan Storch; Hans-Gerhard Löffler; Andrej Hasilik; Jaana Tyynelä; Thomas Braulke
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

Review 4.  Deciphering the molecular basis of breast cancer metastasis with mouse models.

Authors:  Ann E Vernon; Suzanne J Bakewell; Lewis A Chodosh
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

Review 5.  Cathepsin D--many functions of one aspartic protease.

Authors:  Petr Benes; Vaclav Vetvicka; Martin Fusek
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-08       Impact factor: 6.312

Review 6.  Possible role of procathepsin D in human cancer.

Authors:  A Vashishta; M Fusek; V Vetvicka
Journal:  Folia Microbiol (Praha)       Date:  2005       Impact factor: 2.629

7.  New insights into procathepsin D in pathological and physiological conditions.

Authors:  Sujata Saraswat-Ohri; Vaclav Vetvicka
Journal:  N Am J Med Sci       Date:  2011-05

Review 8.  The Potential Role of the Proteases Cathepsin D and Cathepsin L in the Progression and Metastasis of Epithelial Ovarian Cancer.

Authors:  Md Zahidul Islam Pranjol; Nicholas Gutowski; Michael Hannemann; Jacqueline Whatmore
Journal:  Biomolecules       Date:  2015-11-20

9.  Detection of oral squamous cell carcinoma metastasis with cathepsin D: An immunohistochemical approach.

Authors:  Seema Kapoor; Geet Priya Kaur; Pranav Sikka
Journal:  Dent Res J (Isfahan)       Date:  2014-03

10.  Cathepsin D deficiency delays central nervous system myelination by inhibiting proteolipid protein trafficking from late endosome/lysosome to plasma membrane.

Authors:  Da-Zhi Guo; Lin Xiao; Yi-Jun Liu; Chen Shen; Hui-Fang Lou; Yan Lv; Shu-Yi Pan
Journal:  Exp Mol Med       Date:  2018-03-16       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.